D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 91 Citations 37,805 563 World Ranking 5832 National Ranking 271

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Gene

Multiple myeloma, Internal medicine, Surgery, Oncology and Transplantation are his primary areas of study. Hartmut Goldschmidt combines subjects such as Bone marrow and Pathology with his study of Multiple myeloma. Many of his studies on Internal medicine apply to Gastroenterology as well.

The concepts of his Oncology study are interwoven with issues in Daratumumab, Immunology and Hazard ratio. His Transplantation research incorporates elements of Clinical endpoint and Stem cell. His Dexamethasone study combines topics in areas such as Interim analysis and Corticosteroid.

His most cited work include:

  • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma (2128 citations)
  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (1706 citations)
  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (828 citations)

What are the main themes of his work throughout his whole career to date?

Hartmut Goldschmidt mainly focuses on Multiple myeloma, Internal medicine, Oncology, Bortezomib and Surgery. His Multiple myeloma research includes themes of Cancer research, Bone marrow and Transplantation. His research on Internal medicine frequently links to adjacent areas such as Gastroenterology.

He has researched Oncology in several fields, including Hazard ratio, Clinical trial, Immunology and Daratumumab. He studies Bortezomib, namely Carfilzomib. His work deals with themes such as Amyloidosis, Leukapheresis, AL amyloidosis and Urology, which intersect with Surgery.

He most often published in these fields:

  • Multiple myeloma (70.54%)
  • Internal medicine (49.14%)
  • Oncology (28.40%)

What were the highlights of his more recent work (between 2017-2021)?

  • Multiple myeloma (70.54%)
  • Internal medicine (49.14%)
  • Oncology (28.40%)

In recent papers he was focusing on the following fields of study:

His main research concerns Multiple myeloma, Internal medicine, Oncology, Lenalidomide and Bortezomib. His work on Autologous stem-cell transplantation as part of general Multiple myeloma study is frequently linked to In patient, therefore connecting diverse disciplines of science. His Dexamethasone, Daratumumab, Carfilzomib, Hazard ratio and Melphalan study are his primary interests in Internal medicine.

His study looks at the relationship between Oncology and fields such as Newly diagnosed, as well as how they intersect with chemical problems. His Lenalidomide study deals with Maintenance therapy intersecting with Ixazomib. Within one scientific family, Hartmut Goldschmidt focuses on topics pertaining to Clinical trial under Bortezomib, and may sometimes address concerns connected to Intensive care medicine.

Between 2017 and 2021, his most popular works were:

  • Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. (282 citations)
  • Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. (149 citations)
  • A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis (125 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

Hartmut Goldschmidt mainly investigates Multiple myeloma, Internal medicine, Oncology, Lenalidomide and Dexamethasone. Bortezomib is the focus of his Multiple myeloma research. His Oncology study integrates concerns from other disciplines, such as Autologous transplantation, Chemotherapy, Monoclonal antibody and Cohort.

His research investigates the connection with Lenalidomide and areas like Hazard ratio which intersect with concerns in Proportional hazards model. His work on Isatuximab as part of his general Dexamethasone study is frequently connected to In patient, thereby bridging the divide between different branches of science. As a member of one scientific family, he mostly works in the field of Transplantation, focusing on Daratumumab and, on occasion, Phases of clinical research, Gastroenterology and Randomized controlled trial.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin.
The New England Journal of Medicine (2005)

2881 Citations

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)

2775 Citations

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst.
Journal of Clinical Oncology (2015)

1144 Citations

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)

1131 Citations

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Meletios A. Dimopoulos;Albert Oriol;Hareth Nahi;Jesus San-Miguel.
The New England Journal of Medicine (2016)

1081 Citations

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Jesús Fernando San Miguel;Jesús Fernando San Miguel;Katja Weisel;Philippe Moreau;Martha Lacy.
Lancet Oncology (2013)

788 Citations

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua.
Lancet Oncology (2016)

720 Citations

Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma.

Rainer Haas;Robert Möhle;Stefan Frühauf;Hartmut Goldschmidt.
Blood (1994)

706 Citations

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Paul Gerard Richardson;Pieter Sonneveld;Michael Schuster;David Irwin.
Blood (2007)

630 Citations

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani.
Blood (2016)

542 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Hartmut Goldschmidt

Paul G. Richardson

Paul G. Richardson

Harvard University

Publications: 315

Shaji Kumar

Shaji Kumar

Mayo Clinic

Publications: 288

Kenneth C. Anderson

Kenneth C. Anderson

Harvard University

Publications: 281

Meletios A. Dimopoulos

Meletios A. Dimopoulos

National and Kapodistrian University of Athens

Publications: 270

Philippe Moreau

Philippe Moreau

University of Nantes

Publications: 204

Morie A. Gertz

Morie A. Gertz

Mayo Clinic

Publications: 191

S. Vincent Rajkumar

S. Vincent Rajkumar

Mayo Clinic

Publications: 188

Angela Dispenzieri

Angela Dispenzieri

Mayo Clinic

Publications: 181

Antonio Palumbo

Antonio Palumbo

University of Turin

Publications: 178

Nikhil C. Munshi

Nikhil C. Munshi

Harvard University

Publications: 177

Gareth J. Morgan

Gareth J. Morgan

New York University

Publications: 164

Evangelos Terpos

Evangelos Terpos

National and Kapodistrian University of Athens

Publications: 162

Pieter Sonneveld

Pieter Sonneveld

Erasmus University Rotterdam

Publications: 157

Sagar Lonial

Sagar Lonial

Emory University

Publications: 152

Robert Z. Orlowski

Robert Z. Orlowski

The University of Texas MD Anderson Cancer Center

Publications: 150

Maria-Victoria Mateos

Maria-Victoria Mateos

University of Salamanca

Publications: 148

Something went wrong. Please try again later.